Please login to the form below

Not currently logged in
Email:
Password:

Eisai/ UCL partnership grows

Eisai is to extend its partnership with University College London, a UK-based university with which the company has been collaborating with for more than 20 years

Eisai is to extend its partnership with University College London (UCL), a UK-based university with which the company has been collaborating with for more than 20 years.

The new phase will see the Eisai and UCL engage in joint research in neurodegenerative disease including biomarker research into neuroinflammation, neurovascular/mitochondria and proteostasis.

During the course of their partnership which began in 1990, Eisai and UCL established an Eisai research facility on the UCL campus and have forged strong co-operative ties through research activities that included the exchange of personnel.

Additionally Eisai said it plans to submit marketing authorisation applications to the regulatory authorities in the US and Europe for perampanel, a first-in-class, highly selective, non-competitive AMPA-type glutamate receptor antagonist that was created through collaborative with UCL research, to complement its marketed products which include Zonegran (zonisamide), Inovelon (rufinamide) and Zebinix (eslicarbazepine acetate).

26th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics